Litcius/Paper detail

The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice

Qian Zhang, Guoping Liu, Ji‐Bin Liu, Mu Yang, Juan Fu, Guodi Liu, Dehua Li, Zhangjie Gu, Linsong Zhang, Yingjiao Pan, Xingbing Cui, Lu Wang, Lixin Zhang, Xiaoli Tian

2021Molecular Therapy — Oncolytics70 citationsDOIOpen Access PDF

Abstract

, we investigated the effects of MSLN-CAR-T cell therapy against ovarian, breast, and colorectal cancer cell-line-derived xenografts (CDX) and MSLN-positive colorectal and gastric cancer patient-derived xenografts (PDX). MSLN-CAR decreased the growth of MSLN-positive tumors concomitant with significantly increased T cells and cytokine levels compared to the control group. These results indicated that modified MSLN-CAR-T cells could be a promising therapeutic approach for solid tumors.

Topics & Concepts

MesothelinCancer researchChemistryMedicineInternal medicineCancerCAR-T cell therapy researchVirus-based gene therapy research
The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice | Litcius